QCZ484 / Novartis, Argo Biopharma - LARVOL DELTA

RNA interference therapy targeting hepatic angiotensinogen for the treatment of hypertension and cardiovascular disease: a first-in-human and proof-of-concept study (ESC 2026) - "The sustained BP-lowering effects for up to 6 months and the favorable safety of QCZ484 highlight its potential for the treatment of patients with uncontrolled HTN, at a convenient dosing regimen. The similar BP-lowering effects of QCZ484 during nighttime are especially advantageous for managing nocturnal hypertension, because nighttime BP is a strong predictor of future cardiovascular and kidney events."

First-in-human • P1 data • Cardiovascular • Hypertension

A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Dyslipidemia • Familial Hypercholesterolemia • Hypertension • Metabolic Disorders

A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients (clinicaltrials.gov) - P2 | N=385 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Active, not recruiting

Enrollment closed • Cardiovascular • Hypertension

An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients. (clinicaltrials.gov) - P2 | N=323 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Hypertension

A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals

New P2 trial • Cardiovascular • Dyslipidemia • Familial Hypercholesterolemia • Hypertension • Metabolic Disorders

An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients. (clinicaltrials.gov) - P2 | N=323 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals

New P2 trial • Cardiovascular • Hypertension

A Study to Evaluate the Safety of QCZ484 in Healthy and Mild Hypertensive Subjects (ANZCTR) - P1 | N=68 | Completed | Sponsor: Novartis Pharmaceuticals Australia Pty Limited | Recruiting ➔ Completed

Trial completion • Cardiovascular • Hypertension

A Study to Evaluate the Safety of QCZ484 in Healthy and Mild Hypertensive Subjects (clinicaltrials.gov) - P1 | N=56 | Completed | Sponsor: Novartis Pharmaceuticals | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • Hypertension

A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients (clinicaltrials.gov) - P2 | N=380 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Dec 2027 ➔ Apr 2028

Trial completion date • Cardiovascular • Hypertension

A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients (clinicaltrials.gov) - P2 | N=380 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Hypertension

A Study to Evaluate the Safety of QCZ484 in Healthy and Mild Hypertensive Subjects (clinicaltrials.gov) - P1 | N=56 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals

New P1 trial • Cardiovascular • Hypertension

A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients (clinicaltrials.gov) - P2 | N=380 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals

New P2 trial • Cardiovascular • Hypertension